Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
RVPH Stock Price Chart Interactive Chart >
RVPH Price/Volume Stats
| Current price | $4.76 | 52-week high | $6.10 |
| Prev. close | $4.33 | 52-week low | $0.53 |
| Day low | $4.38 | Volume | 253,609 |
| Day high | $4.97 | Avg. volume | 133,935 |
| 50-day MA | $3.99 | Dividend yield | N/A |
| 200-day MA | $2.51 | Market Cap | 97.31M |
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio
Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.
Latest RVPH News From Around the Web
Below are the latest news stories about REVIVA PHARMACEUTICALS HOLDINGS INC that investors may wish to consider to help them evaluate RVPH as an investment opportunity.
RedChip CEO Dave Gentry Invited to Join Forbes Business CouncilRedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council. |
Reviva Pharmaceuticals Announces Letter to ShareholdersCUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareho |
As Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) market cap increased US$11m, insiders who bought last year may be reflecting on buying moreLast week, Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ:RVPH ) insiders, who had purchased shares in the previous 12... |
Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction DataReviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced data from its clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects. The CYP3A4 enzyme is pivotal in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine. Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for schizophrenia. A CYP3A4 inhibitor, itraconazole, slight |
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS |
RVPH Price Returns
| 1-mo | 12.00% |
| 3-mo | 12.00% |
| 6-mo | 605.29% |
| 1-year | 181.66% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 12.00% |
| 2022 | 47.06% |
| 2021 | -66.95% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...